Rap1 Activation Protects Against Fatty Liver and Non-Alcoholic Steatohepatitis Development

Area of Science:

• Metabolic diseases
• Hepatology
• Molecular signaling

Background:

• Hepatic activation of the small G protein Rap1a is suppressed in obesity, leading to increased glucose production and intolerance.
• Rap1a inhibition in obese mouse liver contributes to fatty liver formation, a characteristic of diabetic liver disease.

Conclusions:

• Hepatic Rap1a acts as a crucial suppressor of both hepatic gluconeogenesis and steatosis.
• Inhibition of hepatic Rap1a activity contributes to the pathogenesis of glucose intolerance and NAFLD/NASH.
• Targeting hepatic Rap1a activity presents a promising therapeutic strategy for NAFLD/NASH and associated metabolic disorders.